GENOMEWEB Interview of Ross Bundy, CRISPR QC™ CEO
With $1.6 million of seed funding recently added to its balance sheet, CRISPR QC™ is advancing the commercial development of its data analytics platform for gene editing. READ FULL ARTICLE HERE The San Diego-based startup currently offers an in vitro CRISPR-based assay as a service to help customers gain insights into the performance of their […]
CRISPR QC™ Closes Seed Round at $1.6M and Appoints George Bonaros to Board of Directors
CRISPR QC™ has announced that they have closed their Seed Round at $1.6M and appointed George Bonaros to the Board of Directors to fuel the commercial growth of their CRISPR Analytics Platform™. The round was led by Serra Ventures. READ FULL ARTICLE HERE CRISPR QC’s CRISPR Analytics Platform provides new dimensions of data and analytics […]
GEN FEATURE: Leveraging Modern Electronics to Streamline CRISPR Workflows
READ FULL ARTICLE HERE By Kiana Aran, PhD The adoption of CRISPR-Cas systems in therapeutics development has led to the rapid emergence of several clinical candidates for treating rare and challenging diseases, including sickle-cell anemia, β-thalassemia, Duchenne muscular dystrophy, and ocular diseases. Translation into the clinic has been facilitated by a robust preclinical framework of […]
CRISPR QC™ Appoints Dr. Toby Richardson to CRISPR QC™ Board of Directors
CRISPR QC™ has announced that Toby Richardson, PhD has been appointed to the board of directors. READ FULL ARTICLE HERE CRISPR QC™ has already started proving that the unique capabilities of our CRISPR Analytics Platform™ can interrogate previously unknowable dimensions of gene editing that is translating into real value for our customers, says Ross Bundy, […]
Clinical CRISPR Success Demonstrates Need for Quality Control
The Clinical CRISPR Successes Are Stacking Up. But Where’s the Emphasis on Quality Control? In mid-September, Intellia released some promising data on two of their CRISPR-based therapeutics. These results are a significant milestone for genome editing and validation of its effectiveness in the clinic. However, the safety of CRISPR-based therapeutics has been a major concern […]
How the CRISPR Tomato and Genome Editing is Shaping the Future of Agriculture
How the CRISPR Tomato and Genome Editing is Shaping the Future of Agriculture One of the many applications of CRISPR-based genome editing is in agriculture, as it provides various benefits over conventional crop breeding strategies. Traditionally, crop developers have grappled with costly, laborious, time-consuming, and complicated selective breeding workflows to identify advantageous traits, such as […]
A Guide to CRISPR-Cas Mechanism of Action: Function and Optimization
The Missing Link in Pre-Clinical Genome Editing Workflows Currently, the “gold standard” genome editing workflows only produce one data type: in-cell editing events. With this single parameter, there is just one outcome to optimize around. Discovery programs typically focus on guide RNAs (gRNA) redesign or transfection conditions to maximize sensitivity and selectivity to troubleshoot CRISPR-Cas […]
CRISPR QC™ Accepted into EvoNexus – San Diego’s Premier Startup Incubator
Technology Driven Insights to Improve CRISPR Edit Outcomes READ THE FULL ARTICLE HERE SAN DIEGO–(BUSINESS WIRE)–On August 12, 2022, EvoNexus, California’s leading non-profit tech incubator, selected CRISPR QC™ to become a portfolio company. “Since 2010, EvoNexus portfolio companies have raised over $1.7B with 40 exits totaling over $2.1B” “The right environment and mentorship is critical […]
CRISPR Quality Control with Kiana Aran
Dr. Kiana Aran, co-founder of CRISPR QC™, is featured as a guest on the DNA Today podcast. View the interview below. Associate Professor of Medical Diagnostics and Therapeutics and head of the Aran Lab at Keck Graduate Institute (KGI) where she works to develop CRISPR Quality Control standards. Dr. Aran is also the Chief Scientific […]
Designing & Optimizing Better CRISPR Performance: Why CRISPR QC™ Exists
It’s been one decade and a Nobel Prize since Charpentier, Doudna, and colleagues first demonstrated the programmability of CRISPR-Cas systems.1 Since then, genome editing has exploded into nearly every field of biology. Today, news about editing technology in animals, plants, and humans occurs almost daily. Additional research has revealed a now-massive toolbox of CRISPR-Cas systems, […]
